AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Associates with a LDL Subfraction: Ex vivo and in vitro Studies

By Rizzo R, Barbarossa D, Protopapa F et al.

Background: PCSK9, by modulating the low-density lipoprotein receptor (LDLR) expression, acts as a key regulator of cholesterol metabolism. Circulating PCSK9 is known to associate with apolipoprotein B (apoB)-containing lipoproteins; however, the specific lipoprotein subspecies involved in this association and the impact of lipid-lowering therapies on this interaction remain poorly understood. Research Questions: This study aimed to characterize the distribution of PCSK9 among plasma lipoproteins in hypercholesterolemic subjects before and after treatment with monoclonal antibodies (mAbs) and small interfering RNA (siRNA). Methods: Plasma samples from hypercholesterolemic patients were collected at baseline (T0) and at 1, 3, and 6 months following initiation of therapy with anti-PCSK9 mAbs (alirocumab/evolocumab, n=30) or siRNA (inclisiran, n=19). Lipoproteins were isolated using iodixanol density gradient ultracentrifugation. Subfractions were analyzed with ELISA, colorimetric assays, western blotting, lipidomics, targeted LC-MS proteomics (MRM) for apolipoproteins, and transmission electron microscopy (TEM). In vitro models using HepG2 cells were used to evaluate co-secretion pathways. In vitro interaction was evaluated using immunoprecipitation of apoB following incubation of PCSK9 with VLDL and LDL isolated by KBr density gradient ultracentrifugation. Results: At baseline, 10±4 % (SD) of total circulating PCSK9 was bound to LDL, specifically to a less dense subfraction as shown in Figure 1. Compared to the main LDL peak, this PCSK9-enriched LDL exhibited IDL-like characteristics: a significantly higher percent triglyceride content (20±12% vs 8±7%, p=0.04), lower cholesteryl esters (32±11% vs 40±15%, p=0.04), larger particle diameter measured by TEM, and a pronounced enrichment in apoE, apoC-I, apoC-II, and apoC-III (p<0.05 for all). Anti-PCSK9 mAb therapy induced a 68% reduction in LDL-C and a 10-fold increase in plasma PCSK9 levels, while inclisiran reduced LDL-C by 50% and plasma PCSK9 by 56% at month 3. Remarkably, neither therapy altered the percentage of LDL-associated PCSK9, which remained stable at around 15%, nor the lipid/apolipoprotein composition of the binding subfraction. Preliminary in vitro data confirmed physical binding, but PCSK9 does not appear to be co-secreted with VLDL in the HepG2 model. Conclusions: Circulating lipoprotein-associated PCSK9 is not randomly distributed but selectively confined to a specific IDL-like LDL subfraction. This structural specificity is fully preserved during anti-PCSK9 mAb and siRNA therapies, indicating that lipoprotein binding is regulated independently of the therapeutic PCSK9-LDLR target axis.

doi.org/10.1161/circ.154.suppl_1.11733Interventions

AgingResearch.News